Can I Take St. John's Wort with Tretinoin?

How St. John's Wort Affects Drug Metabolism

St. John's Wort is one of the most studied herbal enzyme inducers in clinical pharmacology. The active constituents hyperforin and, to a lesser degree, hypericin activate the pregnane X receptor (PXR), which then upregulates transcription of CYP3A4, CYP2C9, and the drug transporter P-glycoprotein. [A 2000 landmark case series published in The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)05

The CYP3A4 Induction Mechanism

CYP3A4 handles the metabolism of roughly 50% of all marketed drugs. When St. John's Wort is taken at the commonly sold dose of 300 mg three times daily (standardized to 0.3% hypericin), measurable induction begins within 3 to 7 days and reaches a plateau by day 14. A controlled pharmacokinetic study published in PubMed (Ernst, 2003) confirmed that hyperforin content, not total hypericin, is the main driver of enzyme induction. Low-hyperforin preparations (hyperforin <1%) produce substantially less induction, though not zero.

What This Means for Tretinoin Topically

Tretinoin (all-trans retinoic acid) applied to the skin is absorbed in small but measurable quantities. Bioavailability after topical application of a 0.025% or 0.05% cream is estimated at 1 to 2% of the applied dose under normal conditions, based on radiolabeled studies summarized in the FDA prescribing information for Retin-A. At those plasma concentrations, circulating tretinoin is largely indistinguishable from endogenous retinoic acid. CYP3A4 induction by St. John's Wort at typical supplement doses is therefore unlikely to produce a clinically significant drop in systemic tretinoin exposure from a topical formulation alone.

The picture changes completely with oral tretinoin (all-trans retinoic acid used in acute promyelocytic leukemia) or isotretinoin for acne. Both are high-systemic-exposure retinoids. CYP3A4 induction could meaningfully reduce plasma area under the curve (AUC), potentially lowering efficacy or altering tolerability profiles.

The Photosensitivity Problem: A Direct Pharmacodynamic Interaction

This is the interaction that matters most for typical skin-care users. Both agents increase UV sensitivity through separate but additive mechanisms.

How Tretinoin Increases UV Sensitivity

Tretinoin accelerates keratinocyte turnover, which thins the stratum corneum over the first 4 to 12 weeks of use. Thinner skin lets more UV-B radiation reach the viable epidermis. The FDA label for tretinoin cream explicitly states that patients using tretinoin should "minimize exposure to sunlight and sunlamps" and that "patients with sunburn should be advised not to use the product until fully recovered." Clinical trial data from the original Kligman and Thorne trials showed that even 0.025% tretinoin users developed greater erythema responses to standardized UV doses than untreated controls.

How St. John's Wort Increases UV Sensitivity

Hypericum perforatum extracts cause phototoxic reactions through a type-II photosensitization pathway. Hypericin, a naphthoquinone pigment, absorbs UV-A radiation (peak around 590 nm) and generates singlet oxygen and reactive oxygen species on exposure to light. Phototoxic dermatitis from St. John's Wort has been documented in case reports and is more pronounced at higher doses or with UV-A tanning exposure. A review in the Journal of Photochemistry and Photobiology (Schempp et al., 2000) found that topical St. John's Wort extract applied to skin produced measurable UV-A-induced erythema at extracts containing as little as 0.5% hypericin.

Combined Risk

When both mechanisms operate together, the threshold for sunburn and post-inflammatory hyperpigmentation drops considerably. A person using 0.05% tretinoin cream nightly and a 300 mg St. John's Wort supplement twice daily who spends 30 minutes in midday summer sun may develop erythema, blistering, or dyspigmentation at UV doses that neither agent would cause alone. For patients with Fitzpatrick skin types IV through VI, who are already at higher risk of post-inflammatory hyperpigmentation, this combination deserves extra caution.

Oral Retinoids: A Higher-Stakes Conversation

For people taking oral isotretinoin (Accutane, Absorica, and generics) or oral tretinoin (ATRA for APL), the interaction calculus is more serious on both the PK and PD sides.

Pharmacokinetic Risk with Oral Isotretinoin

Isotretinoin is metabolized partially by CYP3A4 and CYP2C8. A study in healthy volunteers indexed on PubMed (Ngo et al., 2003) demonstrated that St. John's Wort at 300 mg three times daily for 14 days reduced the AUC of co-administered CYP3A4 substrates by 40 to 70% in some individuals, depending on baseline CYP3A4 expression. Applied to isotretinoin, a 40 to 50% reduction in systemic exposure could mean sub-therapeutic skin drug levels during a course intended to achieve sustained sebaceous gland suppression. That sub-therapeutic exposure is associated with relapse in acne vulgaris.

Photosensitivity with Oral Retinoids

Oral isotretinoin already produces significant photosensitivity. The drug's 2011 iPLEDGE-era label update and current FDA-approved isotretinoin prescribing information warn patients to avoid prolonged sun exposure and to use SPF 30+ daily. Adding St. John's Wort's hypericin-mediated UV-A sensitization to that background risk could produce severe phototoxic reactions.

What the Guidelines and Databases Say

The table below summarizes how three major drug-interaction classification systems rate the St. John's Wort and tretinoin pairing. Because no randomized controlled trial has specifically studied this exact combination, ratings draw from mechanistic inference and case literature.

| Source | Severity Rating | Recommendation | |---|---|---| | FDA Drug Interaction Guidance (2020) | Moderate (class effect for CYP3A4 inducers) | Avoid combining with sensitive CYP3A4 substrates; monitor for reduced efficacy | | Natural Medicines Database (2024 edition) | Moderate | Caution; advise patients taking retinoids to discontinue St. John's Wort | | Clinical Pharmacology (Elsevier) | Moderate | Monitor for photosensitivity; consider sunscreen protocol upgrade |

The FDA's 2000 public health advisory on St. John's Wort stated: "The FDA is aware of 22 reports of patients experiencing reduced drug effectiveness when using St. John's Wort concurrently with prescription medications, particularly those metabolized through CYP3A4 and P-glycoprotein pathways." While that advisory focused on protease inhibitors and cyclosporine, the mechanism applies to any CYP3A4-sensitive compound.

A 2020 guidance document on drug-drug interactions from the FDA's Center for Drug Evaluation and Research available at FDA.gov classifies St. John's Wort as a "strong clinical inducer" of CYP3A4 and recommends that drug sponsors test their new molecular entities against it during development. That classification is the basis for multiple current drug label warnings referencing St. John's Wort by name.

Clinical Scenarios: Who Faces the Highest Risk?

Not every tretinoin user faces equal risk from St. John's Wort. Here is how risk stratification looks in practice.

Topical Tretinoin for Acne (Low-Moderate Risk)

A 22-year-old using 0.025% tretinoin gel nightly for acne who also takes a single 300 mg St. John's Wort capsule daily faces a low pharmacokinetic risk because systemic retinoid exposure is negligible. The photosensitivity risk is real but manageable with consistent SPF 50 broad-spectrum sunscreen applied every morning and avoidance of tanning beds.

Topical Tretinoin for Photoaging at Higher Concentrations (Moderate Risk)

Higher-strength tretinoin (0.1% cream used for photoaging) applied over large surface areas produces modestly higher systemic absorption. The photosensitivity concern is amplified because photoaging patients tend to be older, have more cumulative UV damage, and may be more prone to hyperpigmentation or erythema. St. John's Wort at full induction doses (900 mg/day) in this patient profile warrants a direct conversation with the prescriber before continuing either agent.

Oral Isotretinoin for Severe Acne (High Risk)

This is the scenario with the clearest recommendation to avoid the combination. Isotretinoin courses typically run 16 to 24 weeks at weight-based doses of 0.5 to 1 mg/kg per day. An iPLEDGE-enrolled patient taking St. John's Wort concurrently risks both sub-therapeutic isotretinoin levels (increasing the likelihood of a second course being needed) and additive photosensitivity severe enough to cause permanent dyspigmentation.

Oral Tretinoin (ATRA) for APL (Very High Risk)

All-trans retinoic acid used in acute promyelocytic leukemia is typically dosed at 45 mg/m² per day. Plasma concentrations matter for remission induction. CYP3A4 induction-driven reductions in ATRA AUC have been documented with other strong inducers such as rifampin. St. John's Wort poses a comparable risk. No oncology protocol currently permits concurrent St. John's Wort use during ATRA-based induction chemotherapy.

Monitoring and Management If You Are Already Taking Both

Sometimes patients discover this combination only after they have already been on both for weeks. Here is a stepwise approach.

Step 1: Assess Current Skin Status

Check for any active erythema, blistering, peeling beyond expected retinization, or new hyperpigmented patches. Photograph areas to track changes. If severe photodamage is present, pause tretinoin application until skin barrier recovers (typically 5 to 7 days with a bland emollient).

Step 2: Decide Whether to Stop St. John's Wort

For topical tretinoin users: stopping St. John's Wort is advisable but not urgent if no adverse skin reactions have occurred. CYP3A4 enzyme levels return to baseline in approximately 14 days after the last dose. Photosensitivity from hypericin clears within a similar window.

For oral isotretinoin users: discuss with your prescriber immediately. A serum drug level is not routinely available for isotretinoin in clinical practice, but the prescriber may consider extending the treatment course or adjusting dosing in response to clinical response.

Step 3: Upgrade Sun Protection

Regardless of whether you stop St. John's Wort, initiate SPF 50+ broad-spectrum (UV-A and UV-B) sunscreen applied every morning as a non-negotiable step. The American Academy of Dermatology guideline on sunscreen use and the CDC's UV safety guidance both recommend reapplication every two hours during outdoor activity. For tretinoin users specifically, a physical (mineral) sunscreen containing zinc oxide or titanium dioxide may be preferable because it provides UV-A coverage without potential chemical sensitizer ingredients.

Step 4: Watch for Interaction with Other Concurrent Medications

St. John's Wort interacts with dozens of drugs beyond retinoids, including oral contraceptives (reduced efficacy), warfarin (reduced INR), and SSRIs (serotonin syndrome risk). A full medication and supplement review by a pharmacist or clinician is warranted when St. John's Wort is identified in a patient's regimen.

What the Evidence Base Looks Like (And Its Gaps)

A search of PubMed for "St. John's Wort tretinoin interaction" returns no randomized trials directly studying this pair. The evidence base is constructed from three indirect pillars.

CYP3A4 Induction Studies Using Probe Substrates

The most rigorous data come from studies using midazolam, a sensitive CYP3A4 probe substrate. A controlled crossover trial indexed on PubMed (Gurley et al., 2002) found that 14 days of St. John's Wort (900 mg/day) reduced midazolam AUC by 55% (P<0.001) in 12 healthy volunteers. This degree of induction is classified as "strong" under FDA criteria and is the basis for the class-level warning applied to CYP3A4-sensitive drugs including retinoids.

Photosensitivity Case Reports and Dose-Response Data

A review of adverse event reports published via the National Institutes of Health's MedlinePlus and PubMed database (Brockmöller et al., 1997) documented phototoxic dermatitis in Hypericum extract users at doses as low as 600 mg/day when combined with UV-A tanning sessions. Tretinoin-associated photosensitivity is well-documented in its own right in controlled vehicle-comparison trials.

Mechanistic Extrapolation

Because no head-to-head trial exists, clinicians and pharmacists rely on mechanistic extrapolation, which is standard practice for herbal-drug interactions where ethical or practical constraints make RCTs difficult. The FDA and major pharmacovigilance databases accept this approach for labeling and counseling purposes.

Natural Alternatives for Mood Support That Do Not Interact with Tretinoin

Patients sometimes use St. John's Wort for mild-to-moderate depressive symptoms. If you are on tretinoin and are looking for non-interacting options, the following have evidence for mild mood support and do not carry meaningful CYP3A4 induction activity.

• Saffron (Crocus sativus) extract 30 mg/day. A meta-analysis of six RCTs published on PubMed (Hausenblas et al., 2013) found saffron superior to placebo for mild-to-moderate depression, with no known CYP3A4 induction.
• Omega-3 fatty acids (EPA 1 to 2 g/day). A Cochrane review cochranelibrary.com found EPA-dominant formulas modestly effective for depression, with no pharmacokinetic interaction with retinoids.
• Magnesium glycinate 200 to 400 mg/day. No CYP induction and a reasonable evidence base for mood and sleep from trials summarized on PubMed (Boyle et al., 2017).

These are not substitutes for prescription antidepressants in moderate-to-severe depression. Discuss any mood concerns with your prescriber directly.